@article{92f0ac11a66a426a85f9f53aa2c58a1b,
title = "Going Beyond “Bio-markers,” Think “Life-markers”",
author = "Laren Tan and Geoff Chupp and Mario Castro and Monica Kraft",
note = "Funding Information: FINANCIAL/NONFINANCIAL DISCLOSURES: The authors have reported to CHEST the following: L. T. has been a member of the advisory boards for AstraZeneca, Sanofi, Regeneron, and Boehringer Ingelheim; a consultant for Boston Scientific; and a member of the Speakers Bureau for Sanofi, Regeneron, Boehringer Ingelheim, and AstraZeneca. G. C. has been a member of the advisory boards for Genentech, AstraZeneca, Regeneron, Boehringer Ingelheim, GlaxoSmithKline, and Teva; a member of the Speakers Bureau for AstraZeneca, Regeneron, Genentech, Boehringer Ingelheim, GlaxoSmithKline, and Circassia; and a Clinical Trial Principal Investigator for AstraZeneca, Genentech, GlaxoSmithKline, and Holaira. M. C. has been a member of the advisory board for Novartis; a consultant for Sanofi, Genentech, Theravance, VIDA, and TEVA; a member of the Speakers Bureau for AstraZeneca, GlaxoSmithKline, Sanofi, Genentech, and TEVA; has received research funding from the National Institutes of Health, American Lung Association, the Patient-Centered Outcomes Research Institute, AstraZeneca, Chiesi, GlaxoSmithKline, Novartis, and Sanofi; and has received royalties from Elsevier. M. K. has received research funding (funds paid to University of Arizona) from the National Institutes of Health, Sanofi, Regeneron, and Chiesi; has served as a consultant for AstraZeneca and Sanofi; and has received royalties from Elsevier. Funding Information: FINANCIAL/NONFINANCIAL DISCLOSURES: The authors have reported to CHEST the following: L. T. has been a member of the advisory boards for AstraZeneca, Sanofi, Regeneron, and Boehringer Ingelheim; a consultant for Boston Scientific; and a member of the Speakers Bureau for Sanofi, Regeneron, Boehringer Ingelheim, and AstraZeneca. G. C. has been a member of the advisory boards for Genentech, AstraZeneca, Regeneron, Boehringer Ingelheim, GlaxoSmithKline, and Teva; a member of the Speakers Bureau for AstraZeneca, Regeneron, Genentech, Boehringer Ingelheim, GlaxoSmithKline, and Circassia; and a Clinical Trial Principal Investigator for AstraZeneca, Genentech, GlaxoSmithKline, and Holaira. M. C. has been a member of the advisory board for Novartis; a consultant for Sanofi, Genentech, Theravance, VIDA, and TEVA; a member of the Speakers Bureau for AstraZeneca, GlaxoSmithKline, Sanofi, Genentech, and TEVA; has received research funding from the National Institutes of Health , American Lung Association , the Patient-Centered Outcomes Research Institute , AstraZeneca , Chiesi , GlaxoSmithKline , Novartis , and Sanofi ; and has received royalties from Elsevier. M. K. has received research funding (funds paid to University of Arizona ) from the National Institutes of Health , Sanofi , Regeneron , and Chiesi ; has served as a consultant for AstraZeneca and Sanofi; and has received royalties from Elsevier. ",
year = "2020",
month = mar,
doi = "10.1016/j.chest.2019.08.2210",
language = "English (US)",
volume = "157",
pages = "503--505",
journal = "CHEST",
issn = "0012-3692",
publisher = "Elsevier Inc.",
number = "3",
}